Keywords: Pharming, Swedish Orphan Biovitrum, SOBI, Ruconest, Rhucin, Hereditary angioedema, HAE, Balkans, North Africa, Middle East
Pharming extends Ruconest deal with SOBI
Article | 16 August 2011
Netherlands-based biotech firm Pharming Group NV (Euronext: PHARM) has extended its existing agreement with Swedish Orphan Biovitrum (STO: SOBI) to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
